Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DASETTA 7/7/7 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy in women who choose to use an oral contraceptive
Prevention of pregnancy
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (Cr Cl <30 m L/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Cr Cl 30-50 m L/min: Administer every 12 hours. Cr Cl 15-29 m L/min: Administer every 24 hours. Cr Cl <15 m L/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs),Liver disease (discontinue if jaundice or impaired liver function develops),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Irregular bleeding/amenorrhea,Depression
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Renal impairment (creatinine clearance < 30 m L/min),Adrenal insufficiency,History of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Current or past breast cancer (known or suspected),Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms or migraine with aura (if age ≥35),Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Hypersensitivity to any component,Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol exposure, but clinical significance is uncertain. Avoid excessive potassium intake (e.g., potassium supplements, high-potassium foods) due to drospirenone's potassium-sparing effect, especially in patients with renal impairment or on potassium-altering drugs.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
DASETTA 7/7/7 is excreted in breast milk in low concentrations (M/P ratio 0.4–0.6). The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for sedation, poor feeding, and rash.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Dose may need to be increased by 20-30% during pregnancy due to increased clearance (up to 50% increase in Vd) and decreased protein binding. Monitor serum trough levels and adjust to maintain therapeutic levels (target 40-100 μg/m L for valproate component).
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
DASETTA 7/7/7 is a fixed-dose combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg for oral contraception. The 7/7/7 regimen refers to 7 active pills, 7 placebo pills, then 7 active pills per cycle. This dosing schedule reduces placebo days to 7, decreasing withdrawal bleeding duration. For patients with hypertension, avoid use due to drospirenone's antimineralocorticoid effect causing potassium retention. Monitor serum potassium in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Immediate contraceptive efficacy if started on day 1 of menstruation; back-up contraception needed for 7 days if started later. Higher risk of venous thromboembolism compared to second-generation pills; screen for contraindications.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time, even during placebo days.,Placebo pills are inactive; bleeding during this week is normal.,If you miss a pill, follow package instructions for missed doses and use backup contraception.,Do not smoke while taking this medication, especially if over 35 years old.,Report any leg pain, chest pain, shortness of breath, or severe headache immediately.,Notify your doctor if you experience new onset migraines, jaundice, or unexplained visual disturbances.,This product does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DASETTA 7/7/7 vs ALYACEN 1/35, answered by our medical review team.
DASETTA 7/7/7 is a Oral Contraceptive that works by DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DASETTA 7/7/7 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DASETTA 7/7/7 is: One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DASETTA 7/7/7 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DASETTA 7/7/7 is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant s. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.